SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

近年来，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂作为新型降糖药，被发现具有独立于降糖作用的心肾保护效应，逐渐成为CKD合并2型糖尿病（T2D ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ...

Sodium-glucose cotransporter 2 (SGLT2) inhibition seems to reduce the progression of nonsevere aortic stenosis over 5 years, with a larger treatment effect seen in those who take the drugs the longest ...

Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the ...

Among hospitalized adults with type 2 diabetes from 2015 to 2020, 3.7% were prescribed an SGLT2 inhibitor. Only 0.2% of hospitalized adults with type 2 diabetes were prescribed a GLP-1 receptor ...